Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.98B | 4.41B | 4.34B | 3.95B | 3.68B |
| Total Depreciation and Amortization | 206.10M | 190.90M | 186.10M | 178.60M | 175.40M |
| Total Amortization of Deferred Charges | 31.20M | 31.20M | 31.20M | 31.20M | 25.20M |
| Total Other Non-Cash Items | 440.00M | 334.10M | 370.90M | 667.50M | 653.80M |
| Change in Net Operating Assets | -958.60M | -668.50M | -685.90M | -1.20B | -811.50M |
| Cash from Operations | 3.69B | 4.29B | 4.24B | 3.63B | 3.72B |
| Capital Expenditure | -492.30M | -496.80M | -530.30M | -437.60M | -380.80M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -9.06B | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.69B | -386.00M | -791.20M | -507.80M | -1.10B |
| Cash from Investing | -6.87B | -882.80M | -1.32B | -945.40M | -1.48B |
| Total Debt Issued | 4.50B | -- | -- | -- | -- |
| Total Debt Repaid | -1.40M | -1.40M | -1.40M | -1.40M | -1.30M |
| Issuance of Common Stock | 151.60M | 136.60M | 138.00M | 127.70M | 108.00M |
| Repurchase of Common Stock | -1.38B | -2.33B | -2.26B | -2.39B | -2.68B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.70M | -200.00K | -200.00K | -300.00K | -500.00K |
| Cash from Financing | 3.25B | -2.20B | -2.12B | -2.26B | -2.58B |
| Foreign Exchange rate Adjustments | -41.60M | -40.80M | 20.10M | 90.90M | 36.30M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 40.80M | 1.17B | 819.50M | 515.60M | -300.30M |